{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:16:42Z","timestamp":1792815402600,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      This study investigates the theranostic potential of a\n                      <jats:sup>44\/47<\/jats:sup>\n                      Sc-labeled antagonist targeting the gastrin-releasing peptide receptor (GRPR) in prostate and breast tumors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A statine-based GRPR antagonist (AAZTA\n                      <jats:sup>5<\/jats:sup>\n                      -Pip-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH\n                      <jats:sub>2<\/jats:sub>\n                      : LF1) was radiolabeled with scandium-44\/47. Detailed in vitro evaluation was carried out in PC3 and T47D cancer cells. In vivo studies, including blood and organ clearance, plasma protein binding, metabolic stability and SPECT\/CT imaging, were performed in PC3- and T47D-mice. To assess its therapeutic efficacy, PC3-mice were treated with [\n                      <jats:sup>47<\/jats:sup>\n                      Sc]Sc-LF1 either alone or in combination with everolimus.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>47<\/jats:sup>\n                      Sc]Sc-LF1 exhibited high binding affinity, low internalization rate (&lt;\u200910% in PC3 and T47D cells), and favorable pharmacokinetics, including rapid blood clearance and low plasma protein binding. In PC3-mice, it demonstrated high and specific tumor uptake (45.4\u2009\u00b1\u20093.9 and 4.9\u2009\u00b1\u20091.6% I.A.\/g at 4 and 96\u00a0h p.i., respectively), while lower GRPR density in T47D-mice led to reduced uptake (6.1\u2009\u00b1\u20093.9 and 0.7\u2009\u00b1\u20090.1% I.A.\/g at 4 and 72\u00a0h p.i.). Its pharmacokinetics enabled high-contrast SPECT\/CT imaging in both models. Combined treatment with everolimus and [\n                      <jats:sup>47<\/jats:sup>\n                      Sc]Sc-LF1 in PC3-mice, significantly inhibited tumor growth compared to monotherapies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The high tumor uptake in two cancer entities with elevated expression of GRPR and the tumor response (tumor size and survival rate) highlight the significant theranostic potential of [\n                      <jats:sup>44<\/jats:sup>\n                      Sc]Sc\/[\n                      <jats:sup>47<\/jats:sup>\n                      Sc]Sc-LF1 for PET (scandium-44) and SPECT (scandium-47) imaging and radionuclide targeted therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07651-y","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T04:24:19Z","timestamp":1762835059000},"page":"2554-2565","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A true theranostic pair \u2013 44\/47Sc-labeled GRPR antagonist shows great promise for managing prostate and breast cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Naveen","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianna","family":"Bilinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Men\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"L\u00e4ppchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euy Sung","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Zoltowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Pawlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Cieszykowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Mikolajczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"R\u00f6sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Rominger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2198-382X","authenticated-orcid":false,"given":"Eleni","family":"Gourni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"7651_CR1","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s11307-017-1151-1","volume":"20","author":"L Baratto","year":"2018","unstructured":"Baratto L, Jadvar H, Iagaru A. Prostate cancer theranostics targeting gastrin-releasing peptide receptors. Mol Imaging Biol. 2018;20:501\u20139. https:\/\/doi.org\/10.1007\/s11307-017-1151-1.","journal-title":"Mol Imaging Biol"},{"key":"7651_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.cpet.2024.03.004","volume":"19","author":"S Dalm","year":"2024","unstructured":"Dalm S, Duan H, Iagaru A. Gastrin releasing peptide Receptors-targeted PET diagnostics and radionuclide therapy for prostate cancer management: preclinical and clinical developments of the past 5 years. PET Clin. 2024;19:401\u201315. https:\/\/doi.org\/10.1016\/j.cpet.2024.03.004.","journal-title":"PET Clin"},{"key":"7651_CR3","doi-asserted-by":"publisher","unstructured":"Mansi R, Nock BA, Dalm SU, Busstra MB, van Weerden WM, Maina T. Radiolabeled Bombesin Analogs Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13225766.","DOI":"10.3390\/cancers13225766"},{"key":"7651_CR4","doi-asserted-by":"publisher","unstructured":"Nock BA, Kanellopoulos P, Joosten L, Mansi R, Maina T. Peptide radioligands in cancer theranostics: agonists and antagonists. Pharmaceuticals (Basel). 2023;16. https:\/\/doi.org\/10.3390\/ph16050674.","DOI":"10.3390\/ph16050674"},{"key":"7651_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00259-019-04504-3","volume":"47","author":"J Kurth","year":"2020","unstructured":"Kurth J, Krause BJ, Schwarzenb\u00f6ck SM, Bergner C, Hakenberg OW, Heuschkel M. First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [(177)Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47:123\u201335. https:\/\/doi.org\/10.1007\/s00259-019-04504-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7651_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1055\/a-1759-4189","volume":"61","author":"J Kurth","year":"2022","unstructured":"Kurth J, Potratz M, Heuschkel M, Krause BJ, Schwarzenb\u00f6ck SM. GRPr theranostics: current status of imaging and therapy using GRPr targeting radiopharmaceuticals. Nuklearmedizin. 2022;61:247\u201361. https:\/\/doi.org\/10.1055\/a-1759-4189.","journal-title":"Nuklearmedizin"},{"key":"7651_CR7","doi-asserted-by":"publisher","unstructured":"Bandara N, Stott Reynolds TJ, Schehr R, Bandari RP, Diebolder PJ, Krieger S, et al. Matched-pair, (86)Y\/(90)Y-labeled, bivalent RGD\/bombesin antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer. Nucl Med Biol. 2018;62\u20133. https:\/\/doi.org\/10.1016\/j.nucmedbio.2018.06.001.","DOI":"10.1016\/j.nucmedbio.2018.06.001"},{"key":"7651_CR8","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2967\/jnumed.123.266233","volume":"65","author":"N Holzleitner","year":"2024","unstructured":"Holzleitner N, Cwojdzinski T, Beck R, Urtz-Urban N, Hillhouse CC, Grundler PV, et al. Preclinical evaluation of Gastrin-releasing peptide receptor antagonists labeled with (161)Tb and (177)Lu: a comparative study. J Nucl Med. 2024;65:481\u20134. https:\/\/doi.org\/10.2967\/jnumed.123.266233.","journal-title":"J Nucl Med"},{"key":"7651_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.nucmedbio.2020.10.005","volume":"90","author":"S Ferguson","year":"2020","unstructured":"Ferguson S, Wuest M, Richter S, Bergman C, Dufour J, Krys D, et al. A comparative PET imaging study of (44 g)Sc- and (68)Ga-labeled Bombesin antagonist BBN2 derivatives in breast and prostate cancer models. Nucl Med Biol. 2020;90:74\u201383. https:\/\/doi.org\/10.1016\/j.nucmedbio.2020.10.005.","journal-title":"Nucl Med Biol"},{"key":"7651_CR10","doi-asserted-by":"publisher","first-page":"17086","DOI":"10.1038\/s41598-019-52914-y","volume":"9","author":"B Mitran","year":"2019","unstructured":"Mitran B, Thisgaard H, Rinne S, Dam JH, Azami F, Tolmachev V, et al. Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26. Sci Rep. 2019;9:17086. https:\/\/doi.org\/10.1038\/s41598-019-52914-y.","journal-title":"Sci Rep"},{"key":"7651_CR11","doi-asserted-by":"publisher","unstructured":"Siwowska K, Guzik P, Domnanich KA, Monn\u00e9 Rodr\u00edguez JM, Bernhardt P, Ponsard B, et al. Therapeutic potential of (47)Sc in comparison to (177)Lu and (90)Y: preclinical investigations. Pharmaceutics. 2019;11. https:\/\/doi.org\/10.3390\/pharmaceutics11080424.","DOI":"10.3390\/pharmaceutics11080424"},{"key":"7651_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s41181-021-00131-2","volume":"6","author":"R Mikolajczak","year":"2021","unstructured":"Mikolajczak R, Huclier-Markai S, Alliot C, Haddad F, Szikra D, Forgacs V, et al. Production of scandium radionuclides for theranostic applications: towards standardization of quality requirements. EJNMMI Radiopharm Chem. 2021;6:19. https:\/\/doi.org\/10.1186\/s41181-021-00131-2.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"7651_CR13","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.2967\/jnumed.114.141614","volume":"55","author":"C M\u00fcller","year":"2014","unstructured":"M\u00fcller C, Bunka M, Haller S, K\u00f6ster U, Groehn V, Bernhardt P, et al. Promising prospects for 44Sc-\/47Sc-based theragnostics: application of 47Sc for radionuclide tumor therapy in mice. J Nucl Med. 2014;55:1658\u201364. https:\/\/doi.org\/10.2967\/jnumed.114.141614.","journal-title":"J Nucl Med"},{"key":"7651_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.apradiso.2019.05.020","volume":"151","author":"D Pawlak","year":"2019","unstructured":"Pawlak D, Wojdowska W, Parus LJ, Cieszykowska I, Zoltowska M, Garnuszek P, et al. Comparison of separation methods for 47Ca\/47Sc radionuclide generator. Appl Radiat Isot. 2019;151:140\u20134. https:\/\/doi.org\/10.1016\/j.apradiso.2019.05.020.","journal-title":"Appl Radiat Isot"},{"key":"7651_CR15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1089\/cbr.2018.2485","volume":"33","author":"S Huclier-Markai","year":"2018","unstructured":"Huclier-Markai S, Alliot C, Kerdjoudj R, Mougin-Degraef M, Chouin N, Haddad F. Promising scandium radionuclides for nuclear medicine: a review on the production and chemistry up to in vivo proofs of concept. Cancer Biother Radiopharm. 2018;33:316\u201329. https:\/\/doi.org\/10.1089\/cbr.2018.2485.","journal-title":"Cancer Biother Radiopharm"},{"key":"7651_CR16","doi-asserted-by":"publisher","unstructured":"K\u00e1lm\u00e1n-Szab\u00f3 I, Szab\u00f3 JP, Arat\u00f3 V, D\u00e9nes N, Opposits G, J\u00f3szai I, et al. PET probes for preclinical imaging of GRPR-Positive prostate cancer: comparative preclinical study of [(68)Ga]Ga-NODAGA-AMBA and [(44)Sc]Sc-NODAGA-AMBA. Int J Mol Sci. 2022;23. https:\/\/doi.org\/10.3390\/ijms231710061.","DOI":"10.3390\/ijms231710061"},{"key":"7651_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s41181-020-00115-8","volume":"5","author":"M Hofstetter","year":"2020","unstructured":"Hofstetter M, Moon ES, D\u2019Angelo F, Geissb\u00fchler L, Alberts I, Afshar-Oromieh A, et al. Effect of the versatile bifunctional chelator AAZTA(5) on the radiometal labelling properties and the in vitro performance of a Gastrin releasing peptide receptor antagonist. EJNMMI Radiopharm Chem. 2020;5:29. https:\/\/doi.org\/10.1186\/s41181-020-00115-8.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"7651_CR18","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.apradiso.2010.04.003","volume":"68","author":"M Pruszy\u0144ski","year":"2010","unstructured":"Pruszy\u0144ski M, Loktionova NS, Filosofov DV, R\u00f6sch F. Post-elution processing of (44)Ti\/(44)Sc generator-derived (44)Sc for clinical application. Appl Radiat Isot. 2010;68:1636\u201341. https:\/\/doi.org\/10.1016\/j.apradiso.2010.04.003.","journal-title":"Appl Radiat Isot"},{"key":"7651_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2174\/1874471011205030187","volume":"5","author":"F Roesch","year":"2012","unstructured":"Roesch F. Scandium-44: benefits of a long-lived PET radionuclide available from the (44)Ti\/(44)Sc generator system. Curr Radiopharm. 2012;5:187\u2013201. https:\/\/doi.org\/10.2174\/1874471011205030187.","journal-title":"Curr Radiopharm"},{"key":"7651_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ph15020234","author":"C Fersing","year":"2022","unstructured":"Fersing C, Masurier N, Rubira L, Deshayes E, Lisowski V. AAZTA-derived chelators for the design of innovative radiopharmaceuticals with theranostic applications. Pharmaceuticals (Basel). 2022. https:\/\/doi.org\/10.3390\/ph15020234.","journal-title":"Pharmaceuticals (Basel)"},{"key":"7651_CR21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s41181-020-00107-8","volume":"5","author":"JP Sinnes","year":"2020","unstructured":"Sinnes JP, Bauder-W\u00fcst U, Sch\u00e4fer M, Moon ES, Kopka K, R\u00f6sch F. (68)Ga, (44)Sc and (177)Lu-labeled AAZTA(5)-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues. EJNMMI Radiopharm Chem. 2020;5:28. https:\/\/doi.org\/10.1186\/s41181-020-00107-8.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"7651_CR22","doi-asserted-by":"publisher","unstructured":"Kumar N, Bilinska A, Men\u00e9ndez E, L\u00e4ppchen T, Kanellopoulos P, Orlova A. Preclinical evaluation of a 177Lu-labeled Gastrin-Releasing peptide receptor antagonist and prostate cancer treatment with monotherapy and in combination with everolimus. ACS Pharmacol Transl Sci ahead Print. https:\/\/doi.org\/10.1021\/acsptsci.5c00491","DOI":"10.1021\/acsptsci.5c00491"},{"key":"7651_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00259-010-1596-9","volume":"38","author":"R Mansi","year":"2011","unstructured":"Mansi R, Wang X, Forrer F, Waser B, Cescato R, Graham K, et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging. 2011;38:97\u2013107. https:\/\/doi.org\/10.1007\/s00259-010-1596-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7651_CR24","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1007\/s00259-023-06364-4","volume":"50","author":"TST Damiana","year":"2023","unstructured":"Damiana TST, Para\u00efso P, de Ridder C, Stuurman D, Seimbille Y, Dalm SU. Side-by-side comparison of the two widely studied GRPR radiotracers, radiolabeled NeoB and RM2, in a preclinical setting. Eur J Nucl Med Mol Imaging. 2023;50:3851\u201361. https:\/\/doi.org\/10.1007\/s00259-023-06364-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7651_CR25","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1021\/jm5012066","volume":"58","author":"R Mansi","year":"2015","unstructured":"Mansi R, Abiraj K, Wang X, Tamma ML, Gourni E, Cescato R, et al. Evaluation of three different families of Bombesin receptor radioantagonists for targeted imaging and therapy of Gastrin releasing peptide receptor (GRP-R) positive tumors. J Med Chem. 2015;58:682\u201391. https:\/\/doi.org\/10.1021\/jm5012066.","journal-title":"J Med Chem"},{"issue":"8","key":"7651_CR26","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1021\/mp500671j","volume":"12","author":"E Gourni","year":"2015","unstructured":"Gourni E, Del Pozzo L, Kheirallah E, Smerling C, Waser B, Reubi JC. Copper-64 labeled macrobicyclic sarcophagine coupled to a GRP receptor antagonist shows great promise for PET imaging of prostate cancer. Mol Pharm. 2015;12(8):2781\u201390. https:\/\/doi.org\/10.1021\/mp500671j.","journal-title":"Mol Pharm"},{"key":"7651_CR27","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.3892\/ijo.2016.3429","volume":"48","author":"B Mitran","year":"2016","unstructured":"Mitran B, Varasteh Z, Selvaraju RK, Lindeberg G, S\u00f6rensen J, Larhed M, et al. Selection of optimal chelator improves the contrast of GRPR imaging using Bombesin analogue RM26. Int J Oncol. 2016;48:2124\u201334. https:\/\/doi.org\/10.3892\/ijo.2016.3429.","journal-title":"Int J Oncol"},{"key":"7651_CR28","doi-asserted-by":"publisher","first-page":"752","DOI":"10.2967\/jnumed.114.153023","volume":"56","author":"SU Dalm","year":"2015","unstructured":"Dalm SU, Martens JW, Sieuwerts AM, van Deurzen CH, Koelewijn SJ, de Blois E, et al. In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer. J Nucl Med. 2015;56:752\u20137. https:\/\/doi.org\/10.2967\/jnumed.114.153023.","journal-title":"J Nucl Med"},{"key":"7651_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.nucmedbio.2016.11.004","volume":"45","author":"I Popp","year":"2017","unstructured":"Popp I, Del Pozzo L, Waser B, Reubi JC, Meyer PT, Maecke HR, et al. Approaches to improve metabolic stability of a statine-based GRP receptor antagonist. Nucl Med Biol. 2017;45:22\u20139. https:\/\/doi.org\/10.1016\/j.nucmedbio.2016.11.004.","journal-title":"Nucl Med Biol"},{"key":"7651_CR30","doi-asserted-by":"publisher","first-page":"896","DOI":"10.2967\/jnumed.124.269132","volume":"66","author":"V Felber","year":"2025","unstructured":"Felber V, Holzleitner N, Joksch M, Suhrbier T, von Amsberg G, Schwarzenb\u00f6ck S, et al. First-in-human serum stability studies of [(177)Lu]Lu-AMTG: a step toward improved GRPR-targeted radiopharmaceutical therapy. J Nucl Med. 2025;66:896\u20139. https:\/\/doi.org\/10.2967\/jnumed.124.269132.","journal-title":"J Nucl Med"},{"key":"7651_CR31","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2967\/jnumed.112.114082","volume":"54","author":"A Roivainen","year":"2013","unstructured":"Roivainen A, K\u00e4hk\u00f6nen E, Luoto P, Borkowski S, Hofmann B, Jambor I, et al. Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med. 2013;54:867\u201372. https:\/\/doi.org\/10.2967\/jnumed.112.114082.","journal-title":"J Nucl Med"},{"key":"7651_CR32","doi-asserted-by":"publisher","first-page":"762","DOI":"10.2967\/jnumed.112.112169","volume":"54","author":"RA Dumont","year":"2013","unstructured":"Dumont RA, Tamma M, Braun F, Borkowski S, Reubi JC, Maecke H, et al. Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with Rapamycin. J Nucl Med. 2013;54:762\u20139. https:\/\/doi.org\/10.2967\/jnumed.112.112169.","journal-title":"J Nucl Med"},{"key":"7651_CR33","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc1362","volume":"4","author":"MA Bjornsti","year":"2004","unstructured":"Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4:335\u201348. https:\/\/doi.org\/10.1038\/nrc1362.","journal-title":"Nat Rev Cancer"},{"key":"7651_CR34","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/s0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449\u201356. https:\/\/doi.org\/10.1016\/s0140-6736(08)61039-9.","journal-title":"Lancet"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07651-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07651-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07651-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:38:46Z","timestamp":1771479526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07651-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7651"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07651-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by local authorities and are in compliance with the institutional guidelines (Animal License Nr: BE63\/2021; 33892).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Axel Rominger is an editor of the EJNMMI. All other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}